The endothelin B receptor plays a crucial role in the adhesion of neutrophils to the endothelium in sickle cell disease

Although the primary origin of sickle cell disease is a hemoglobin disorder, many types of cells contribute considerably to the pathophysiology of the disease. The adhesion of neutrophils to activated endothelium is critical in the pathophysiology of sickle cell disease and targeting neutrophils and their interactions with endothelium represents an important opportunity for the development of new therapeutics. We focused on endothelin-1, a mediator involved in neutrophil activation and recruitment in tissues, and investigated the involvement of the endothelin receptors in the interaction of neutrophils with endothelial cells. We used fluorescence intravital microscopy analyses of the microcirculation in sickle mice and quantitative microfluidic fluorescence microscopy of human blood. Both experiments on the mouse model and patients indicate that blocking endothelin receptors, particularly ETB receptor, strongly influences neutrophil recruitment under inflammatory conditions in sickle cell disease. We show that human neutrophils have functional ETB receptors with calcium signaling capability, leading to increased adhesion to the endothelium through effects on both endothelial cells and neutrophils. Intact ETB function was found to be required for tumor necrosis factor α-dependent upregulation of CD11b on neutrophils. Furthermore, we confirmed that human neutrophils synthesize endothelin-1, which may be involved in autocrine and paracrine pathophysiological actions. Thus, the endothelin-ETB axis should be considered as a cytokine-like potent pro-inflammatory pathway in sickle cell disease. Blockade of endothelin receptors, including ETB, may provide major benefits for preventing or treating vaso-occlusive crises in sickle cell patients.

[1]  B. Le Pioufle,et al.  Effects of Poloxamer 188 on red blood cell membrane properties in sickle cell anaemia , 2016, British journal of haematology.

[2]  P. Frenette,et al.  Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. , 2016, Blood.

[3]  P. Sundd,et al.  Quantitative microfluidic fluorescence microscopy to study vaso-occlusion in sickle cell disease , 2015, Haematologica.

[4]  J. Faith,et al.  Neutrophil ageing is regulated by the microbiome , 2015, Nature.

[5]  L. Kiger,et al.  Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease. , 2015, Blood.

[6]  P. Frenette,et al.  Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. , 2013, Hematology. American Society of Hematology. Education Program.

[7]  C. Ince,et al.  Microcirculation , 2012, Springer US.

[8]  F. Cunha,et al.  Endothelin-1 induces neutrophil recruitment in adaptive inflammation via TNFα and CXCL1/CXCR2 in mice. , 2012, Canadian journal of physiology and pharmacology.

[9]  P. Frenette,et al.  HETEROTYPIC INTERACTIONS ENABLED BY POLARIZED NEUTROPHIL MICRODOMAINS MEDIATE THROMBO-INFLAMMATORY INJURY , 2009, Nature Medicine.

[10]  D. Kaul,et al.  Sickle Red Cell–Endothelium Interactions , 2009, Microcirculation.

[11]  Xiu‐da Shen,et al.  Tezosentan, a novel endothelin receptor antagonist, markedly reduces rat hepatic ischemia and reperfusion injury in three different models , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[12]  S. Aractingi,et al.  Efficacy of the endothelin receptor blocker bosentan for refractory sickle cell leg ulcers , 2008, British journal of haematology.

[13]  Y. Castier,et al.  Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. , 2008, The Journal of clinical investigation.

[14]  J. Pollock,et al.  Endothelin and NOS1/nitric oxide signaling and regulation of sodium homeostasis , 2008, Current opinion in nephrology and hypertension.

[15]  R. Girot,et al.  Urinary endothelin-1 as a marker of renal damage in sickle cell disease. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  D. Webb,et al.  Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptor-mediated and nitric oxide-dependent mechanism. , 2004, Journal of the American Society of Nephrology : JASN.

[17]  Ş. Çetinel,et al.  Endothelin-3 induced mesenteric vasoconstriction and PMN infiltration in the rat small intestine: role of endothelin receptors , 2004, Regulatory Peptides.

[18]  S. Simon,et al.  Inflammatory potential of neutrophils detected in sickle cell disease , 2004, American journal of hematology.

[19]  Minsoo Kim,et al.  Bidirectional Transmembrane Signaling by Cytoplasmic Domain Separation in Integrins , 2003, Science.

[20]  A. Scarpa,et al.  Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease-specific lung injury induced by hypoxia/reoxygenation. , 2003, Blood.

[21]  J. Goldman,et al.  Relationship between the clinical manifestations of sickle cell disease and the expression of adhesion molecules on white blood cells , 2002, European journal of haematology.

[22]  J. Elion,et al.  Hydroxyurea corrects the dysregulated L-selectin expression and increased H(2)O(2) production of polymorphonuclear neutrophils from patients with sickle cell anemia. , 2002, Blood.

[23]  B. Coller,et al.  Primary role for adherent leukocytes in sickle cell vascular occlusion: A new paradigm , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[25]  S. Davidge,et al.  Matrix metalloproteinases regulate neutrophil‐endothelial cell adhesion through generation of endothelin‐1[1–32] , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  L. De Franceschi,et al.  Formation of dense erythrocytes in SAD mice exposed to chronic hypoxia: evaluation of different therapeutic regimens and of a combination of oral clotrimazole and magnesium therapies. , 1999, Blood.

[27]  A. Duits,et al.  Neutrophil activation in sickle cell disease , 1999, Journal of leukocyte biology.

[28]  J. Filep,et al.  Endothelin‐1 enhances neutrophil adhesion to human coronary artery endothelial cells: role of ETA receptors and platelet‐activating factor , 1999, British journal of pharmacology.

[29]  M. Yanagisawa,et al.  Elevation of blood pressure by genetic and pharmacological disruption of the ETB receptor in mice. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.

[30]  M. Telfer,et al.  Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis. , 1998, Blood.

[31]  R. Moore,et al.  Elevated plasma endothelin‐1 levels in sickle cell anemia: Relationships to oxygen saturation and left ventricular hypertrophy , 1998, American journal of hematology.

[32]  I. Okpala,et al.  Peripheral blood neutrophil count and candidacidal activity correlate with the clinical severity of sickle cell anaemia (SCA) , 1998, European journal of haematology.

[33]  R. Myklebust,et al.  Endothelin-1 causes sequential trapping of platelets and neutrophils in pulmonary microcirculation in rats. , 1996, The American journal of physiology.

[34]  J. Elferink,et al.  Modulation of human neutrophil chemotaxis by the endothelin-B receptor agonist sarafotoxin S6c. , 1996, Chemico-biological interactions.

[35]  C. Caramelo,et al.  Role of endothelin in the pathophysiology of renal ischemia-reperfusion in normal rabbits. , 1996, Kidney international.

[36]  D. Faller,et al.  Sickle erythrocytes, after sickling, regulate the expression of the endothelin-1 gene and protein in human endothelial cells in culture. , 1995, The Journal of clinical investigation.

[37]  C. Caramelo,et al.  Effects of aspirin on platelet-neutrophil interactions. Role of nitric oxide and endothelin-1. , 1995, Circulation.

[38]  M. Trudel,et al.  The transgenic SAD mouse: a model of human sickle cell glomerulopathy. , 1994, Kidney International.

[39]  B. M. Koster,et al.  Endothelin-induced activation of neutrophil migration. , 1994, Biochemical pharmacology.

[40]  O. Castro,et al.  The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. , 1994, Blood.

[41]  O. Platt,et al.  Mortality in sickle cell disease. Life expectancy and risk factors for early death. , 1994, The New England journal of medicine.

[42]  S. Ozaki,et al.  Clearance of circulating endothelin-1 by ETB receptors in rats. , 1994, Biochemical and biophysical research communications.

[43]  M. Goligorsky,et al.  Termination of endothelin signaling: Role of nitric oxide , 1994, Journal of cellular physiology.

[44]  D. Gómez-Garre,et al.  Aggregation of human polymorphonuclear leukocytes by endothelin: role of platelet-activating factor. , 1992, European journal of pharmacology.

[45]  P. Ratcliffe,et al.  Organ distribution of the three rat endothelin messenger RNAs and the effects of ischemia on renal gene expression. , 1992, The Journal of clinical investigation.

[46]  G. Davis The Mac-1 and p150,95 beta 2 integrins bind denatured proteins to mediate leukocyte cell-substrate adhesion. , 1992, Experimental cell research.

[47]  P. Romeo,et al.  Towards a transgenic mouse model of sickle cell disease: hemoglobin SAD. , 1991, The EMBO journal.

[48]  J. Egido,et al.  Inhibition by L-arginine of the endothelin-mediated increase in cytosolic calcium in human neutrophils. , 1991, Biochemical and biophysical research communications.

[49]  J. Vane,et al.  The biosynthesis of endothelin-1 by human polymorphonuclear leukocytes. , 1991, Biochemical and biophysical research communications.

[50]  K. Takeshige,et al.  Endothelin-1 enhances superoxide generation of human neutrophils stimulated by the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine. , 1990, Biochemical and biophysical research communications.

[51]  R S Reneman,et al.  Wall shear rate in arterioles in vivo: least estimates from platelet velocity profiles. , 1988, The American journal of physiology.

[52]  S. Baez,et al.  An open cremaster muscle preparation for the study of blood vessels by in vivo microscopy. , 1973, Microvascular research.

[53]  J. Elion,et al.  ET-1 and ecNOS gene polymorphisms andsusceptibility to acute chest syndrome and painful vaso-occlusive crises in children with sickle cell anemia. , 2006, Haematologica.

[54]  E. Hatzimichael,et al.  Circulating endothelin-3 levels in patients with sickle cell disease during hydroxyurea treatment. , 2004, Haematologica.

[55]  B. M. Koster,et al.  The effect of endothelin-2 (ET-2) on migration and changes in cytosolic free calcium of neutrophils , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[56]  J. Elion,et al.  Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells , 2003, The Pharmacogenomics Journal.

[57]  R. Kedzierski,et al.  Endothelin system: the double-edged sword in health and disease. , 2001, Annual review of pharmacology and toxicology.

[58]  R. Ware,et al.  Prevalence and clinical correlates of glomerulopathy in children with sickle cell disease. , 2000, The Journal of pediatrics.

[59]  T. Pearson,et al.  Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64. , 1998, Blood.

[60]  Scott T. Miller,et al.  Cerebrovascular accidents in sickle cell disease: rates and risk factors. , 1998, Blood.

[61]  P. Gasparini,et al.  Increased Levels of Endothelin-1 in Plasma of Sickle Cell Anemia Patients , 1998 .

[62]  A. Taylor,et al.  Blocked ETA receptors prevent ischemia and reperfusion injury in rat lungs. , 1996, Journal of applied physiology.

[63]  Jan G. R. Elferink,et al.  Stimulation and Inhibition of Neutrophil Chemotaxis by Endothelin‐3 , 1995, Journal of cardiovascular pharmacology.

[64]  A. Doherty,et al.  Characterization of endothelins as chemoattractants for human neutrophils. , 1994, Life sciences.

[65]  T. Hoang,et al.  Sickle cell disease of transgenic SAD mice. , 1994, Blood.